Viewing StudyNCT06119217

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 7:44 PM
Last Modification Date: 2024-10-26 @ 3:13 PM
Study NCT ID: NCT06119217
Status: RECRUITING
Last Update Posted: 2024-07-03
First Post: 2023-09-22
Brief Title: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Sponsor: Trishula Therapeutics Inc
Organization: Trishula Therapeutics Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Pancreatic Cancer
Keywords:
Name View
metastatic View
Cancer View
Pancreatic Adenocarcinoma View
Combination Therapy View
CD39 View
Adenosine Pathway View
Immunotherapy View
Immuno-oncology View
Pancreatic Ductal Adenocarcinoma View
PD-1 Checkpoint Inhibitor View
Budigalimab View
TTX-030 View